Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022 VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders…


Previous articlePsychedelics: Past, Present, Future – Webinar
Next articleMeet Microdosing TikTok—And Why the Community Matters